Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hematologic Malignancies
Dermatology
Questions discussed in this category
How do you approach balancing the potential risk of worsening actinic damage and maintaining CTCL clearance in patients treated with nb-UVB?
2 Answers available
What first-line therapies do you recommend for patients with folliculotropic mycosis fungoides?
Has topical dapsone worked?
3 Answers available
What is the role of radiotherapy in cutaneous pseudolymphoma?
Are there particular indications you use for RT? i.e. multiply recurrent, refractory to other therapies, near critical structures, unresectable (or re...
1 Answer available
Do you hold histone deacetylase (HDAC) inhibitors for patients receiving palliative radiation therapy for cutaneous lymphomas?
If so, how long before/after radiation?
1 Answer available
How do you differentiate atopic dermatitis from mycosis fungoides histologically?
1 Answer available
How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?
Do you have a preferred sequence of therapies for diffuse skin limited MF?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
15453
14344
12699
14126
12382
12066
8485
Papers discussed in this category
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Related Topics in Hematologic Malignancies
Breast Cancer
Head and Neck Cancers
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers
Pediatric Oncology
Sarcoma